Emeryville, CA – April 3, 2025 – Octant, Inc. (“Octant”), an AI-enabled drug discovery company developing correctors for misfolding diseases, announced today that Cofounder and President Ramsey Homsany will participate in a virtual fireside chat at the RBC 2025 Ophthalmology Conference on Friday, April 4th at 9:15am PT.
Octant is a small molecule drug discovery company developing correctors for protein misfolding diseases. Octant’s platform, The Navigator, combines high-throughput synthetic biology, generative chemistry, and AI/ML to discover and develop therapeutics against complex cellular mechanisms in human cells. Their pipeline is led by correctors programs for autosomal dominant Retinitis Pigmentosa (adRP) and Fabry Disease (FD), and includes several other programs across oncology and other serious diseases. For more information visit www.octant.bio.